Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 401

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 401
---
 in finished dosage form. In addition, Scilex Pharma agreed to appoint the Licensee as its exclusive distributor of the Lido Product in the Licensee Territory during the Lido License Term.

The Lido License Term commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined
therein), unless earlier terminated.

Parent Guarantee for Lido License Agreement

On February 22, 2025, in connection with Lido License Agreement, we entered into the Parent Guarantee with the Licensee, pursuant to which
we agreed to guarantee the due and proper performance of Scilex Pharma’s obligations under the Lido License Agreement on the terms and conditions set forth in the Parent Guarantee.

252

Pursuant to the terms of the Parent Guarantee, we shall provide the Licensee with written notice of any Change of Control (as defined therein) of Scilex Pharma within five business days after the
consummation of such Change of Control, and the Parent Guarantee and the guarantee obligations shall automatically terminate upon the consummation of such Change of Control.

The foregoing summaries of the Lido License Agreement and the Parent Guarantee do not purport to be complete and are qualified in their
entirety by reference to the full text of the Lido License Agreement and the Parent Guarantee, a copy of each of which is filed as an exhibit to our Current Report on Form 8-K filed on
February 27, 2025.

Gloperba-Elyxyb Royalty Purchase Agreement

As contemplated by the Term Sheet in respect of the Royalty and Exclusive Rights described therein, on February 28, 2025 (the
“Closing Date”), we entered into the Gloperba-Elyxyb Royalty Purchase Agreement with Scilex Pharma and the Gloperba-Elyxyb RPA Purchasers. Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma sold to the
Gloperba-Elyxyb RPA Purchasers the Gloperba-Elyxyb Purchased Receivables with respect to the Gloperba-Elyxyb Covered Products.

In
consideration of the Further Deferral and representing the “grant of the Royalty and Exclusive Rights” (as defined in the Term Sheet), during the period commencing on the Closing Date and expiring on the tenth anniversary of the Closing
Date (the “Payment Term”), Scilex Pharma shall pay to each Gloperba